Follistatin-Related Fusion Proteins
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 62/007,908, filed Jun 4, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,010,498 | Methods for Treatment of Amyotrophic Lateral Sclerosis with Follistatin Fusion Proteins In force · High confidence UsedRemaining | Acceleron Pharma Inc. | In force | High confidence | ||
| US 10,023,621 | Follistatin-Related Fusion Proteins In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | ||
| US 11,497,792 | Methods for Treatment of Duchenne Muscular Dystrophy with Follistatin Polypeptides In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | ||
| US 10,765,626 | Methods for Treatment of Charcot-Marie-Tooth Disease with Follistatin Polypeptides In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | ||
| US 10,954,279 | Methods and Compositions for Treatment of Disorders with Follistatin Polypeptides In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.